TNBC occurs in approximately 15% to 20% of breast cancers worldwide, mostly in young women and is clinically defined by the lack of expression of the receptors for estrogen and progesterone (ER/PR) and the absent overexpression of the human epidermal growth factor receptor 2 (HER2) [1]. This evidence concerns the gene ERBB2 and breast cancer.